Mereo BioPharma Group (LTS:0A9G) Total Liabilities : $15.42 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mereo BioPharma Group Total Liabilities?

Mereo BioPharma Group's Total Liabilities for the quarter that ended in Dec. 2024 was $15.42 Mil.

Mereo BioPharma Group's quarterly Total Liabilities declined from Jun. 2024 ($17.48 Mil) to Sep. 2024 ($16.21 Mil) and declined from Sep. 2024 ($16.21 Mil) to Dec. 2024 ($15.42 Mil).

Mereo BioPharma Group's annual Total Liabilities declined from Dec. 2022 ($26.01 Mil) to Dec. 2023 ($15.96 Mil) and declined from Dec. 2023 ($15.96 Mil) to Dec. 2024 ($15.42 Mil).

Mereo BioPharma Group Total Liabilities Historical Data

The historical data trend for Mereo BioPharma Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Total Liabilities Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

106.19

51.85

26.01

15.96

15.42

Mereo BioPharma Group Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															15.96	13.10	17.48	16.21	15.42

Mereo BioPharma Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mereo BioPharma Group's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	13.848	+	(0.187	+	1.386
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	15.42

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	76.39	-	60.969
	=	15.42

Mereo BioPharma Group's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	13.848	+	(0.187	+	1.386
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	15.42

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	76.39	-	60.969
	=	15.42

Mereo BioPharma Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (LTS:0A9G) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

MREO:USA MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Mereo BioPharma Group Headlines

No Headlines